Physician profile
Paige Powell
NPI 1639977135
$2,610.01
in general payments reported to CMS, 2019-2025
16 companies · $2,610 in 2025
The $2,610 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,204 · Travel and Lodging: $327 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.76 |
| Travel and Lodging | $327.26 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $977.57 | 2025 | Tyvaso, Remodulin, Orenitram |
| Actelion Pharmaceuticals US, INC. | $274.00 | 2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $250.01 | 2025 | Winrevair, Keytruda, Keytruda Qlex |
| Verona Pharma, INC. | $222.05 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals Lp | $216.64 | 2025 | Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.58 | 2025 | Jascayd, Ofev |
| Genzyme Corporation | $88.59 | 2025 | |
| Viatris Specialty LLC | $85.19 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $83.92 | 2025 | Glassia |
| Lilly USA, LLC | $83.07 | 2025 | Zepbound, Mounjaro |
| Grifols USA, LLC | $66.94 | 2025 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $59.55 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $36.71 | 2025 | Acthar |
| Recordati_rare_diseases_inc. | $22.39 | 2025 | Isturisa |
| Breas Medical, INC. | $20.47 | 2025 | Vivo 45 Ls |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $18.33 | 2025 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.